Also known as: epithalon, ala-glu-asp-gly, agedg
Latest evidence update: 2002-09-01
Strongest in Consistency (35). Held back by Sample size (5).
Limited to weak study designs or thin reporting.
Few independent replications; results not yet robust.
Small combined sample; treat as preliminary.
Mixed direction across studies.
Mostly pre-2020 research; updates may be needed.
No quantified outcomes yet. Once we have studies with measurable endpoints, you will see per-outcome magnitude here.
Recommended: Research protocols use injectable peptide; oral formulations have unproven bioavailability.
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.